A5064845217- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac electrophysiology and arrhythmias
- Venous Thromboembolism Diagnosis and Management
- Diabetes Treatment and Management
- Cardiac pacing and defibrillation studies
- Cardiac Structural Anomalies and Repair
- Health Systems, Economic Evaluations, Quality of Life
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Cardiac Imaging and Diagnostics
- Cardiomyopathy and Myosin Studies
- COVID-19 Clinical Research Studies
- Blood Pressure and Hypertension Studies
- COVID-19 and healthcare impacts
- Cardiac Health and Mental Health
- Lipoproteins and Cardiovascular Health
- Cardiovascular Health and Disease Prevention
- Potassium and Related Disorders
- Metabolism, Diabetes, and Cancer
- Cardiovascular Issues in Pregnancy
- Acute Ischemic Stroke Management
- Pharmaceutical Economics and Policy
University of Belgrade
2016-2025
Univerzitetski Klinički Centar Srbije
2011-2024
Serbian Academy of Sciences and Arts
2024
Centar za Promociju Nauke
2013-2022
Uppsala University
2021-2022
Hospital Universitario Virgen de la Arrixaca
2022
Centro de Investigación en Red en Enfermedades Cardiovasculares
2022
Universidad de Murcia
2022
Associazione Nazionale Medici Cardiologi Ospedalieri
2022
Laboratoire Informatique d'Avignon
2022
Background— The CHA 2 DS -VASc (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, previous Stroke/transient ischemic attack [TIA], Vascular disease, 65–74 and Sex category [female gender]) schema recently has been introduced to complement the CHADS >75 stroke or TIA) score improve identification of atrial fibrillation (AF) patients at “truly low risk” for thromboembolism. We tested predictive ability -VASc, , van Walraven risk stratification schemes in a cohort...
Primary heart involvement in systemic sclerosis may cause morpho-functional and electrical cardiac abnormalities is a common of death. The absence clear definition primary limits our understanding ability to focus on clinical research. We aimed create an expert consensus for sclerosis.
Takotsubo syndrome (TTS) still remains as an enigmatic phenomenon. In particular, long-term challenges (including clinical recurrence and persistent symptoms) specific entities in the setting of TTS have been evolving areas interest. On other hand, a significant gap exists regarding proper risk-stratification this phenomenon short long terms. The present paper, second part (part-2) consensus report, aims to discuss less well-known aspects including entities, after recovery risk-stratification.